These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

940 related items for PubMed ID: 26058549

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases.
    Rinaudo-Gaujous M, Paul S, Tedesco ED, Genin C, Roblin X, Peyrin-Biroulet L.
    Aliment Pharmacol Ther; 2013 Oct; 38(8):914-24. PubMed ID: 24001128
    [Abstract] [Full Text] [Related]

  • 63. Biosimilars: in support of extrapolation of indications.
    Ebbers HC.
    J Crohns Colitis; 2014 May; 8(5):431-5. PubMed ID: 24594005
    [Abstract] [Full Text] [Related]

  • 64.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 65.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 66.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68. [Biosimilars--opportunity or threat?].
    Swierkot J.
    Wiad Lek; 2013 May; 66(2 Pt 2):200-5. PubMed ID: 25775818
    [Abstract] [Full Text] [Related]

  • 69. Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico.
    Mayoral-Zavala A, Esquivel-Aguilar A, Del Real-Calzada CM, Gutiérrez-Grobe Y, Ramos-García J, Rocha-Ramírez JL, Rojas-Illanes MF, Rubio-Martínez B, Sánchez-Chávez X, Yamamoto-Furusho JK, Grupo Académico y de Investigación en Crohn y Colitis Ulcerosa Idiopática de México (GAICCUM).
    Rev Gastroenterol Mex (Engl Ed); 2018 May; 83(4):414-423. PubMed ID: 29685744
    [Abstract] [Full Text] [Related]

  • 70. The Current State of Dermatologists' Familiarity and Perspectives of Biosimilars for the Treatment of Psoriasis: A Global Cross-Sectional Survey.
    Manalo IF, Gilbert KE, Wu JJ.
    J Drugs Dermatol; 2017 Apr 01; 16(4):336-343. PubMed ID: 28403267
    [Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
    Schreiber S, Panés J, Kwon B, Hong S, Peyrin-Biroulet L.
    Expert Rev Gastroenterol Hepatol; 2015 Apr 01; 9 Suppl 1():5-15. PubMed ID: 26395530
    [Abstract] [Full Text] [Related]

  • 73.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 74.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76. Clinical considerations for the development of biosimilars in oncology.
    Socinski MA, Curigliano G, Jacobs I, Gumbiner B, MacDonald J, Thomas D.
    MAbs; 2015 Apr 01; 7(2):286-93. PubMed ID: 25621390
    [Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y, Cutroneo PM, Marcianò I, Giezen T, Atzeni F, Trifirò G.
    Drug Saf; 2018 Nov 01; 41(11):1013-1022. PubMed ID: 29796832
    [Abstract] [Full Text] [Related]

  • 79.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 80.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.